Systemic Steroid Treatment of Paradoxical Upgrading Reaction in Patients with Lymph Node Tuberculosis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Sir—We read with interest the article by Hawkey et al. [1]. They report that paradoxical upgrading reactions (PUR) to antituberculous treatment occurred in 23% of non—HIV-infected patients. This is the highest percentage ever reported in an immunocompetent population, in whom PUR is usually <5% [2, 3]. A plausible explanation is that the authors' definition of PUR includes worsening of tuberculosis in patients treated for only 10 days, and the presence of a discharging sinus and persistent lymphadenopathy. We think that a minimum of 4 weeks should elapse between the start of antituberculous therapy and the development of PUR because, by definition, an initial clinical improvement should take place before worsening [2–4]. Also, because a discharging sinus was a well-known complication of benign tuberculous lymph node disease in the preantibiotic era, it is difficult to justify as a defining symptom of PUR. These considerations are important in the analysis of the effect of corticosteroids in the treatment of PUR. In contrast with previous studies [2–5], Hawkey et al. [1] did not find any evidence of a beneficial effect and questioned the effectiveness of corticosteroids to treat PUR. We think that their analysis could be biased by their definition of PUR, by the different use of steroids depending upon the severity of disease, and by the difficulties involved in the follow-up of the evolution of PUR by means of medical charts. In our experience with patients with severe PUR to antituberculous treatment after exposure to infliximab, anti-inflammatory treatment played an important role [4]. In our cohort study, surgery to control PUR was required in all patients that did not receive anti-inflammatory agents. Conversely, no patient treated with anti-inflammatory drugs required surgery. Our results, and the well-known beneficial effects of corticosteroid therapy in reducing edema in intracranial tuberculomas [5–7], would suggest that severe PUR must be treated with steroids. Dosing and duration of treatment have not been defined; our limited experience would indicate that 4–6 weeks of oral steroids is adequate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Clinical and Experimental Immunology
Kay, H. (1966) · PubMed Central · Cited by 2,177
Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608
Cheng, V., Ho, P., Lee, R., Chan, K., Chan, K., Woo, P., Lau, S., & Yuen, K. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0821-2 · Cited by 342
Afghani, B., & Lieberman, J. M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.6.1092 · Cited by 270
Cheng, V. C. C., Yam, W. C., Woo, P. C. Y., Lau, S. K. P., Hung, I. F. N., Wong, S. P. Y., Cheung, W. C., & Yuen, K. Y. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0998-z · Cited by 186
Moreno, C., Taverne, J., Mehlert, A., Bate, C., Brealey, R., Meager, A., Rook, G. A. W., & Playfair, J. H. L. (1989) · PubMed Central · Cited by 185
Garcia Vidal, C., Rodriguez Fernandez, S., Martinez Lacasa, J., Salavert, M., Vidal, R., Rodriguez Carballeira, M., & Garau, J. (2005) · Clinical Infectious Diseases · doi:10.1086/427941 · Cited by 180
Self-citationHawkey, C. R., Yap, T., Pereira, J., Moore, D. A. J., Davidson, R. N., Pasvol, G., Kon, O. M., Wall, R. A., & Wilkinson, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/429317 · Cited by 170
Ustianowski, A., Shaffer, R., Collin, S., Wilkinson, R. J., & Davidson, R. N. (2005) · Journal of Infection · doi:10.1016/j.jinf.2004.07.006 · Cited by 166
Wallis, R. S., Amir-Tahmasseb, M., & Ellner, J. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3348 · Cited by 158
Cited by
Current diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
Tuberculosis-immune reconstitution inflammatory syndrome
Lanzafame, M., & Vento, S. (2016) · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · doi:10.1016/j.jctube.2016.03.002 · Cited by 154
Géri, G., Passeron, A., Heym, B., Arlet, J. B., Pouchot, J., Capron, L., & Ranque, B. (2012) · Infection · doi:10.1007/s15010-012-0376-9 · Cited by 98
“Nevertheless, corticosteroids seem to be safe and are strongly recommended by several authors for the treatment of severe PR [23].”
BackgroundRuf, M., Chauty, A., Adeye, A., Ardant, M.-F., Koussemou, H., Johnson, R. C., & Pluschke, G. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001252 · Cited by 83
The risk of tuberculosis in patients treated with TNF antagonists
Salgado, E., & Gómez-Reino, J. J. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.6 · Cited by 53
Hsu, D. C., Faldetta, K. F., Pei, L., Sheikh, V., Utay, N. S., Roby, G. A., Rupert, A. W., Fauci, A. S., & Sereti, I. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ841 · Cited by 49
Lekhbal, A., Kaoutar, C., Halily, S., Abada, R., Rouadi, S., Roubal, M., & Mahtar, M. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.05.006 · Cited by 26
Martins, T. G., Trigo, G., Fraga, A. G., Gama, J. B., Longatto‐Filho, A., Saraiva, M., Silva, M. T., Castro, A. G., & Pedrosa, J. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001925 · Cited by 26
Martínez-Planas, A., Baquero‐Artigao, F., Santiago, B., Fortuny, C., Méndez-Echevarría, A. M., del Rosal, T., Alonso, M. B., Gale, I., Guerrero, C., Blázquez‐Gamero, D., et al. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.05.008 · Cited by 19
“Paradoxical reaction was defined as clinical or radiological worsening of existing TB lymphadenitis or development of new lesions in patients receiving anti-tuberculous medication who initially improved on treatment (29).”
BackgroundPornsuriyasak, P., & Suwatanapongched, T. (2015) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2014.14212 · Cited by 14
Respuesta paradójica durante el tratamiento tuberculostático en pacientes inmunocompetentes
Fernández-Fúnez, Á. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.12.020 · Cited by 14
Rakotoarivelo, R. A., Vandenhende, M.-A., Michaux, C., Morlat, P., & Bonnet, F. (2013) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.08.014 · Cited by 10
Réaction paradoxale à la fin du traitement antituberculeux chez le sujet immunocompétent
Bacha, S., Khémiri, M., Racil, H., Hantous, S., Chaouch, N., Cheikhrouhou, S., Chabbou, A., & Megdiche, M. L. (2016) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2016.09.002 · Cited by 6
Solid Swellings of the Anterior Triangle: Cervical Lymphadenopathy
Sakr, M. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-32118-4_3 · Cited by 5
Reply to Garcia Vidal and Garau
Wilkinson, R. J., Hawkey, C. R., & Davidson, R. N. (2005) · Clinical Infectious Diseases · doi:10.1086/432813 · Cited by 3
Dutt, N. C., & Gupta, A. (2014) · National Journal of Community Medicine · Cited by 2
The role of repeated aspirations in the treatment of tubercular cervical lymphadenitis
Goswami, R., Gangwani, A., Goswami, D., & Shrivastav, P. (2019) · Tropical Journal of Ophthalmology and Otolaryngology · doi:10.17511/jooo.2019.i01.02 · Cited by 1
Tuberculosis‐immune reconstitution inflammatory syndrome in HIV ‐negative children
Palamit, A., Tovichien, P., & Amornsitthiwat, R. (2022) · Respirology Case Reports · doi:10.1002/rcr2.945 · Cited by 2
Paradoxical reactions during Antituberculosis therapy - A single-center prospective analysis
Hammi, S., Zimed, N., Bouti, K., & Bourkadi, J. E. (2015) · International Journal of Medicine and Surgery · doi:10.15342/ijms.v2i2.75 · Cited by 1
Tuberculose, agents anti-TNF-α et autres immunosuppresseurs
Liote, H. A., & Leveiller, G. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)56023-2 · Cited by 1
A Case of Paradoxical Reaction Development during Antituberculosis Therapy
Cho, Y. B., Chu, M. S., Ryu, H. S., Choi, S. C., & Seo, G. S. (2015) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2015.65.5.306
Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
Pombo‐Suárez, M., & Gómez-Reino, J. J. (2020) · Technical report · doi:10.1016/b978-0-444-64217-2.00009-9
Mastitis granulomatosa tuberculosa en varón, con respuesta paradójica a la terapia antituberculosa
Cubas, H. V., & Paz, M. E. P. (2020) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2020.11.004
Une réaction paradoxale neurologique compliquant une tuberculose cutanée
Sellami, K., Mseddi, M., Fourati, H., Koubâa, M., Elleuch, E., Masmoudi, A., Mnif, Z., Turki, H., & Jemâa, M. B. (2017) · La revue médicale de Madagascar. · doi:10.62606/rmmcc00204
Metadata
- Authors
- Vidal, C. G., & Garau, J.
- Affiliations
- University Hospital Mútua de Terrassa (ES)
- ORCID
- Garau, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-15
- Volume
- 41
- Issue
- 6
- Pages
- 915-916
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2063508336
- Cited by
- 24
- References
- 12
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 1 · 2017: 1 · 2016: 2 · 2015: 4 · 2014: 1 · 2013: 1 · 2012: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculous lymphadenitis, systemic corticosteroid therapy, infliximab, discharging sinuses, lymphadenopathy, surgical management, anti-inflammatory therapy
- MeSH terms
- Adrenal Cortex Hormones, Anti-Inflammatory Agents, Humans, Tuberculosis, Lymph Node
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.